Thursday, November 19, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 55
Confirmed by 2 outlets

FDA clears Regeneron's Livsayis, a gMG shot dosed four times a year

Regeneron won FDA approval for Livsayis (cemdisiran), the first siRNA therapy approved for generalized myasthenia gravis and the only gMG treatment dosed subcutaneously four times a year. The green light rests on Phase 3 NIMBLE data showing fast, deep symptom control that held steady between quarterly shots. It's also Regeneron's first approved siRNA therapy and its first neurology medicine.

By the Paparazzi desk November 18, 2026 · 3:03 PM · Sources: 2 outlets · 0 views
Fact boxTrust 58/100 · Developing
What we verified
  • 2 sources report it: finance.yahoo.com, neurologylive.com.
  • The source published it on Nov 18, 2026 at 3:03 PM.
What we couldn't

Nothing open. Every check passed.

The FDA approved Livsayis (cemdisiran) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive, the most common form of the disease, Regeneron announced on Nov. 18. The company says it is the first and only siRNA therapy approved in gMG, and the only FDA-approved gMG treatment given subcutaneously four times a year. It also marks a double first for Regeneron: the company's first approved siRNA therapy and its first neurology medicine. The announcement came via a paid press release distributed by GlobeNewswire.

Livsayis is a C5-directed small interfering RNA therapeutic. It works by reducing levels of circulating complement component factor 5 protein, which limits terminal complement activation, a key driver of gMG. Instead of frequent infusions, patients get a shot every three months.

Sponsored

The approval leans on the Phase 3 NIMBLE trial, where Livsayis posted a 4.5-point improvement on the Myasthenia Gravis-Activities of Daily Living total score at 24 weeks, compared with a 2.2-point improvement on placebo. That worked out to a placebo-adjusted improvement of 2.3 points (p=0.0005). The share of MG-ADL responders with at least a 3-point improvement hit 76.6% on Livsayis versus 44.1% on placebo (p<0.001). MG-ADL tracks daily functions like talking, chewing, swallowing, breathing, vision and mobility.

On the Quantitative Myasthenia Gravis scale, which measures muscle function including vision, speaking and swallowing, breathing and limb mobility, Livsayis delivered a 4.2-point improvement at 24 weeks against 1.5 points for placebo, a placebo-adjusted gain of 2.8 points (p=0.0015). QMG responders with at least a 5-point improvement reached 48.4% versus 19.0% on placebo (p<0.001). Patients showed a clinically meaningful MG-ADL benefit of 2.5 points as early as two weeks in, deepening over time, and scores held through 24 weeks with no sign of waning efficacy.

Tuan Vu, M.D., professor of neurology at the University of South Florida Morsani College of Medicine and a global principal investigator of NIMBLE, pointed to the daily toll of the disease. People with gMG face unpredictable muscle weakness and fatigue, plus exacerbations that can be life-threatening, he said, and many still get suboptimal control. Vu called the NIMBLE results evidence that a first-of-its-kind approach targeting a key disease driver can offer a compelling option, with rapid, deep control maintained through the end of each dosing interval.

TopicsRegeneron Pharmaceuticals · LIVSAYIS · cemdisiran · FDA · Tuan Vu · NIMBLE trial · NASDAQ: REGN · generalized myasthenia gravis

Share

Written by AI from verified reporting.

More stories

  • Health & science 23:18 UTC · 2 hours ago · cardiovascularbusiness.com · 0 views
    FDA moves to yank liquid statin FloLipid off US shelves
  • Health & science 22:51 UTC · 2 hours ago · cnbc.com · Caught by @bayu.lestari45 · 0 views
    FDA's Case Against Cheap-Drug Sellers Rests on a Rival CEO Turned Informant
  • Health & science 22:46 UTC · 2 hours ago · x.com · 0 views
    Adults Ask About Another Measles Shot as US, Mexico and Bolivia Lose Elimination Status
  • Health & science 19:31 UTC · 5 hours ago · finance.yahoo.com · 1 view
    Ionis' Tryngolza becomes EU's first RNA therapy for severe high triglycerides
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.